5 October 2022 - NICE has published evidence based recommendations on the use of ozanimod hydrochloride for the treatment of adults with moderate to severe active ulcerative colitis when conventional or biological treatments cannot be tolerated or are not working well enough.

Ozanimod hydrochloride is recommended as an option for the treatment of adults with moderate to severe active ulcerative colitis only if:

• Conventional treatment cannot be tolerated or is not working well enough and infliximab is not suitable, or
• Biological treatment cannot be tolerated or is not working well enough, and
• Celgene provides it according to the commercial arrangement

Read NICE technology appraisal guidance